drugset / Trial / NCT02836353

Metabolic Consequences of Gastrointestinal Surgery

NCT02836353

Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

Surgery on the gastrointestinal (GI) tract results in profound changes to the metabolic profile. This is well described, including the rapid resolution of diabetes seen after bariatric surgery. The underlying pathophysiology, and incidence in lean patients undergoing surgery for cancer, is somewhat less described. The investigators plan to assess the symptomatic and glycaemic profile, as well as causative pathways, for metabolic symptoms in patients after surgery on the GI tract. The investigators will use glucose tolerance tests, physiological challenges with somatostatin analogues and antibiotics, and assess tissue transcriptomic changes.

Timeline

Start
2017-01
Primary completion
2019-03-11
Completion
2019-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifaximin Other / unclassified 400 mg
Subject Somatostatin Traditional medicine (herbal / TCM) 100 ug